Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo, FDA, Vanderbilt to Study Genetic Basis of Long QT Side Effect

NEW YORK, Dec. 17 (GenomeWeb News) - The US Food and Drug Administration, GlaxoSmithKline, and Vanderbilt University will use First Genetic Trust's enTRUST genetic-banking and research technology to conduct a post-marketing study into the genetic basis for drug-induced Long QT.

 

Long QT is a side effect for many different classes of drugs characterized by risk of developing heart arrhythmias that may, in rare cases, lead to sudden death.

 

GSK will use FGT's system to recruit Long QT patients electronically through Vanderbilt and a network of referral sites. The company will use collected blood samples and clinical data to study the genetics of the side effect across several classes of drugs.

 

The FDA will facilitate patient enrollment by sending letters through MedWatch to health professionals who have reported a case of Long QT or Torsades de Pointe, a particularly severe form of the side effect.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.